EU regulators impose interim measures against Illumina in Grail deal By Reuters
[ad_1]

BRUSSELS (Reuters) – EU antitrust regulators on Monday announced interim measures against U.S. life sciences company Illumina (NASDAQ:) for for closing its $8 billion cash-and-stock takeover of cancer detection test maker Grail deal before gaining approval.
The European Commission stated that these measures were designed to maintain and restore effective competition, while it reviews the Illumina acquisition of Grail.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]